Amarantus Announces the Presentation of Data Showing MANF”s Positive Effect on Retinal Function at Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

ByConnor Hodde

Amarantus BioScience Holdings, Inc. announced the presentation of positive preclinical data for MANF (mesencephalic-astrocyte-derived neurotrophic factor) in retinitis pigmentosa (RP) at the Association for Research in Vision and Ophthalmology Annual Meeting, being held in Denver, CO. The results from preclinical studies demonstrate that MANF preserves the light-sensing function of photoreceptor cells in a genetic model of RP.

Rong Wen, M.D., Ph.D., Professor of Ophthalmology, at the Bascom Palmer Eye Institute at the University of Miami Miller School of Medicine, poster on MANF entitled,”ERG preservation by intravitreal injected recombinant mesencephalic astrocyte-derived neurotrophic factor (MANF) in rd10 mice,” disclosed the results of the effect of MANF on the electrophysiological activities of retinal cells in the rd10 mice, a retinal degeneration model of RP carrying the Pde6brd10 mutation. The data demonstrated that intravitreal injection of recombinant human MANF preserves the light-sensing function of photoreceptor cells, as measured by the b-wave amplitude using electroretinography.

Read the entire article here.

Similar Posts

Retinal Ischemia Tied to Variant of Acute Macular Neuroretinopathy

ByConnor Hodde

Paracentral acute middle maculopathy is a newly identified variant of acute macular neuroretinopathy that appears to result from retinal capillary ischemia, according to a retrospective observational case series. “This has been traditionally a very rare disease but now with advanced retinal imaging systems such as spectral domain optical coherence tomography (SD-OCT) and infrared reflectance imaging…

Interim results from clinical trial demonstrate safety of cell-based therapy for retinitis pigmentosa

ByConnor Hodde

Regenerative medicine company jCyte and the Sue & Bill Gross Stem Cell Research Center at the University of California, Irvine report that their investigational therapy for retinitis pigmentosa (RP) has demonstrated a favorable safety and tolerability profile in an ongoing Phase I/II clinical trial.  The cell-based approach taken is intended to rescue sick and dying…

Solving Three Major Age-related Eye Conditions in One Go

ByConnor Hodde

Vascular endothelial growth factor A (VEGF-A) is looking like more of an optical troublemaker than ever before – as well as its link with wet age-related macular degeneration (AMD), it also might be causing dry AMD and even age-related cataracts.  Therefore, Massachusetts General Hospital researcher and paper author, Dr Alexander Marneros, is looking at what processes…

Curing blindness by repairing corneas with invisible films

ByConnor Hodde

The University of Melbourne–lead team of researchers have grown corneal cells on a layer of film that can be implanted in the eye to help the cornea heal itself. They have successfully restored vision in animal trials and are aiming to move to human trials next year.  “The hydrogel film we have developed allows us to…

Brolucizumab as Good as Aflibercept for Neovascular AMD

ByConnor Hodde

Brolucizumab is noninferior to aflibercept and requires less-frequent injections for patients with neovascular age-related macular degeneration (nAMD), according to results from two phase-3 trials. Earlier this month, Novartis announced that the U.S. Food and Drug Administration accepted the company’s brolucizumab application for the treatment of nAMD. Reductions in central subfield thickness (CST) on optical coherence…